Provider Briefing: The Dexmethylphenidate Shortage in 2026

The stimulant medication shortage has tested providers and patients alike for over three years. Dexmethylphenidate — both immediate-release (IR) and extended-release (XR) formulations — has been among the more severely affected medications. If you prescribe Dexmethylphenidate (brand name Focalin/Focalin XR), this update covers what you need to know heading into 2026, along with practical strategies for managing your patients through continued supply disruptions.

Shortage Timeline: How We Got Here

The broader ADHD stimulant shortage began in October 2022, when the FDA first confirmed supply disruptions for Amphetamine mixed salts (Adderall). Dexmethylphenidate was subsequently added to the ASHP drug shortage list as manufacturers reported production shortfalls.

Key milestones:

• Late 2022: FDA acknowledges Adderall shortage; cascading effects hit other stimulants including Dexmethylphenidate as patients and providers pivot between medications.
• 2023: Multiple generic Dexmethylphenidate XR manufacturers report back orders. A joint DEA-FDA statement reveals manufacturers were producing only ~70% of their allotted quotas in 2022.
• 2024: DEA transitions to a semi-annual quota allocation system for non-injectable controlled substances. During the transition, some manufacturers experienced delays in receiving production quotas, further constraining supply.
• Late 2025: DEA officially increases aggregate production quotas for stimulant medications. Additional generic manufacturers enter or resume Dexmethylphenidate production.
• Early 2026: Dexmethylphenidate XR remains on the ASHP shortage list, though supply is gradually improving. IR tablets are generally more available than XR capsules.

Prescribing Implications

The shortage has several direct implications for prescribers:

Dose and Formulation Flexibility

Patients may need to switch between IR and XR formulations or adjust to available strengths. When a patient's usual Dexmethylphenidate XR 20 mg is unavailable, consider:

• Two Dexmethylphenidate XR 10 mg capsules (if that strength is available)
• Switching to IR tablets dosed twice daily (total daily dose equivalent)
• Converting to Methylphenidate equivalents: Dexmethylphenidate dose × 2 = approximate Methylphenidate dose

Therapeutic Substitution Considerations

When Dexmethylphenidate is entirely unavailable, the most common substitutions include:

• Methylphenidate (Ritalin, Concerta, Ritalin LA): Closest pharmacologic equivalent. Double the Dexmethylphenidate dose for Methylphenidate dosing.
• Amphetamine/Dextroamphetamine (Adderall, Adderall XR): Different mechanism; no direct dose conversion. Start at a conservative dose and titrate.
• Lisdexamfetamine (Vyvanse): Prodrug of Dextroamphetamine. Good option for patients who need abuse-deterrent properties. Generic available since 2023.
• Atomoxetine (Strattera): Non-stimulant option not affected by Schedule II supply constraints. Takes 4–6 weeks for full effect; not suitable as an acute bridge.

For a patient-oriented overview of these options, see Alternatives to Dexmethylphenidate.

Documentation and Prior Authorization

Insurance plans are generally accommodating shortage-related switches, but documentation helps. Note in the chart that the switch is due to a supply shortage, not a clinical failure. This can expedite prior authorization for the alternative medication and facilitate a return to Dexmethylphenidate when supply normalizes.

Current Availability Picture

As of early 2026, the availability landscape looks like this:

• Dexmethylphenidate IR (generic): Generally available at many pharmacies, though intermittent spot shortages persist for certain strengths.
• Dexmethylphenidate XR (generic): Still in active shortage. Several manufacturers (Par, Sandoz, and others) have reported varying availability across strengths. 5 mg, 10 mg, and 15 mg strengths tend to be more available than 20 mg, 25 mg, and 30 mg.
• Focalin XR (brand): Available from Novartis but at significantly higher cost ($250–$400+ for 30 capsules).

Providers can direct patients to Medfinder for Providers to help locate real-time pharmacy availability in their area.

Cost and Access Considerations

Cost remains a significant barrier for many patients, particularly those without insurance or with high-deductible plans:

• Generic Dexmethylphenidate IR: $19–$66 for 30 tablets (cash price; as low as $19 with discount cards)
• Generic Dexmethylphenidate XR: $30–$150 for 30 capsules depending on strength
• Brand Focalin XR: $250–$400+ for 30 capsules

Cost-mitigation strategies to discuss with patients:

• Discount cards (SingleCare, GoodRx) can reduce generic prices significantly
• Novartis offers a Focalin XR copay card: patient pays first $10, Novartis covers up to $60/month (commercially insured patients only)
• Novartis Patient Assistance Foundation provides free medication to eligible uninsured patients
• NeedyMeds and RxAssist list additional assistance programs

For patient-facing cost guidance, refer them to How to Save Money on Dexmethylphenidate.

Tools and Resources for Your Practice

Several tools can help streamline shortage management in your practice:

• Medfinder for Providers: Real-time pharmacy availability search. Recommend to patients or use at point of care to identify pharmacies with current stock before sending a prescription.
• ASHP Drug Shortage Resource Center: Official shortage tracking with manufacturer-specific updates and estimated resupply dates.
• FDA Drug Shortage Database: Federal-level shortage tracking and manufacturer communications.
• State PDMP systems: Continue checking your state's Prescription Drug Monitoring Program as required for all Schedule II prescriptions.

Looking Ahead: What to Expect

The trajectory for Dexmethylphenidate supply in 2026 is cautiously optimistic:

• DEA quota increases should continue to translate into greater manufacturing output throughout the year
• Additional generic market entrants are expected to further diversify supply
• However, demand growth shows no signs of slowing — ADHD diagnosis rates continue to climb, particularly in adult populations
• Full resolution of the stimulant shortage is unlikely before late 2026 at the earliest

The practical implication: continue planning for intermittent supply disruptions and maintain dose-conversion references and alternative prescribing protocols in your practice.

Final Thoughts

The Dexmethylphenidate shortage has been one of the most prolonged and impactful drug shortages in recent memory. As prescribers, the most valuable thing we can do is stay informed, maintain flexible prescribing strategies, and connect patients with tools like Medfinder to help them locate their medications. The shortage is slowly improving, but proactive management remains essential.

For a companion guide on helping patients navigate the search for their medication, see How to Help Your Patients Find Dexmethylphenidate in Stock.